Pfizer (PFE) investor relations material

Strategic transformation and financial performance

• Achieved consistent revenue and EPS beats for 2024, 2025, and Q1 2026, despite a sharp decline in COVID-related business.

• Major cost reductions were enabled by targeted AI deployment and business model changes.

• Shifted focus from pandemic reliance to a diversified portfolio, emphasizing oncology, obesity, and immunology.

• Completed $70 billion in M&A, with three deals (Seagen, Biohaven, Metsera) representing 80% of capital deployed and showing strong growth.

• Commercial model, manufacturing cost structure, and R&D focus have been restored and optimized post-COVID.

R&D productivity and pipeline highlights

• R&D productivity is top quartile in technical merit and success rates, but focus has shifted to better product selection for market success.

• Oncology pipeline is a key strength, with lorlatinib setting a new standard in thoracic cancer and significant advances in urothelial and breast cancer.

• Vaccine portfolio saw successes with Lyme disease (70%+ efficacy) and pediatric Prevnar 25, with plans for Prevnar 35.

• Obesity program advancing with data supporting a product launch in two years, aiming for monthly dosing and strong efficacy.

• Immune inflammation pipeline includes promising trispecific antibody data.

Capital allocation and business development

• Maintains $7 billion in M&A capacity post-Hengrui deal, with flexibility for larger deals if needed.

• Current strategy focuses on pipeline bolt-ons and international partnerships, especially in China.

• Seagen, Biohaven, and Metsera acquisitions are delivering strong portfolio growth.